Former UCLA Decathlete Sentenced to 17.5 Years in Jail for Securities Fraud

Nov.22.2022
Former UCLA Decathlete Sentenced to 17.5 Years in Jail for Securities Fraud
Former UCLA decathlete sentenced to 210 months in prison for defrauding investors of over $45 million.

LOS ANGELES – A former decathlete from the University of California, Los Angeles who once competed for the Philippine national team was sentenced to 210 months in prison today for fraudulently raising over $45 million from investors. These investors were told their funds would be used to support a company marketing cannabis e-cigarettes.


David Joseph Bunevacz, 53 years old from the city of Calabasas, has been sentenced by US District Judge Dale S. Fischer to pay $35,267,851 in restitution. During today's sentencing hearing, Judge Fischer noted that Bunevacz had "bullied those who thought he was their friend," and that the severity of his actions cannot be measured solely in monetary terms.


Judge Fischer also found that even during the probationary period following his conviction in state court, Bunevacz continued to carry out his plan and concluded that "neither criminal conviction nor threat of imprisonment could persuade [Bunevacz] to become a law-abiding citizen.


On July 18th, Bunevacz admitted to committing securities fraud and telecommunications fraud. He has been in federal custody since his arrest on April 5th in connection to this case.


Going back to 2010, Bunevacz created various business entities, including CB Holding Group Corp. and Caesarbrutus LLC, which he claimed were involved in the marijuana industry and the sale of electronic cigarettes containing marijuana products such as CBD oil and THC.


Bunevacz reportedly lied to at least one investor about his supposed long-term partnership with a Chinese manufacturer of disposable e-cigarettes. According to court documents, he claimed to have obtained "pesticide-free raw material oil" that was sent to a laboratory for flavor infusion using a "proprietary custom process" to make vape flavoring smooth and discrete. He also provided fake documents such as bank statements, invoices, and purchase orders to support his claims of the company's success and need for investor funding.


Bunevacz did not use these funds to provide financial support for the operation of his business - despite the fact that some of his victims are currently experiencing serious financial difficulties. Instead, he diverted the vast majority of the funds to finance his own luxurious lifestyle, which includes a mansion in Calabasas, trips to Las Vegas, expensive jewelry and designer handbags, extravagant birthday parties for his daughter, and horses.


To create the appearance of conducting legitimate business activities for his company, Bunevacz registered various shell companies, including several with similar or identical names to legitimate marijuana businesses. To conceal his control over these shell companies and related bank accounts, Bunevacz listed other individuals, including his stepdaughter, as executives of the shell companies.


Bunevacz's blog praises his success as a former decathlete competing in the Philippines, and highlights appearances of his wife and daughter on a reality show. According to sworn statements submitted in support of the criminal prosecution, despite promoting his background, Bunevacz made efforts to conceal negative information from investors, such as his conviction for a felony in 2017 for illegally selling securities.


After an investor discovered a lawsuit against Bunevacz, the latter sent a forged version of a settlement agreement via email, claiming he had received $325,000 as part of the settlement. However, in reality, it was Bunevacz who agreed to pay $325,000 to settle the claim.


According to government records, Bunevacz raised approximately $45,227,266 from over 100 victim investors through his marijuana company. Judge Fischer found that Bunevacz caused approximately $35,267,851 in losses.


A prosecutor argued in a sentencing memorandum that "the violation of personal dignity, emotional harm, and lasting trauma caused by [Bunevacz] are reminiscent of the harm typically associated with violent crimes." "Furthermore, [Bunevacz] victimized over 100 individuals, causing harm on a scale rarely seen.


The Federal Bureau of Investigation, the Criminal Investigation Division of the Internal Revenue Service, and the Los Angeles County Sheriff's Department conducted an investigation into the matter. The Securities and Exchange Commission provided significant assistance. Assistant U.S. Attorney Alexander B. Schwab of the Major Frauds Section filed charges in this case.


Statement:


This article is based on third-party information that has been translated using machine translation, and is only intended for exchange and learning within the industry.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of its content. The translation of this article is only intended for industry communication and research purposes.


Due to limitations in the translation process, the translated article may not fully reflect the intended meaning of the original. Please refer to the original text for accuracy.


2FIRSTS maintains complete consistency with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


The compilation of the information herein is copyrighted by the original media source and author. If infringement occurs, please contact us for prompt removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane 2026 Update Adds Nine Trials, Keeps High-Certainty Finding That Nicotine E-Cigarettes Improve Quit Rates Over NRT
Cochrane’s 2026 update of its living review on electronic cigarettes for smoking cessation included 80 randomized controlled trials involving 29,861 adult smokers, with nine trials added in this update. The review retained its high-certainty conclusion that nicotine e-cigarettes increase smoking cessation rates compared with nicotine replacement therapy. In absolute terms, about 10 in 100 people using nicotine e-cigarettes may quit smoking for at least six months, compared with about 6 in 100 using NRT. The review found no clear difference in serious adverse event rates between the two groups, while longer-term safety and the relative effectiveness of newer device types remain less certain.
Sep.07
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Vaping brand PIXL has introduced the PIXL 5K reusable prefilled pod device in the UK, featuring a 2ml prefilled pod and a 4ml refill container with a combined e-liquid capacity of 6ml. The device uses 20mg/ml nicotine salt e-liquid and is advertised to deliver up to approximately 5,000 puffs. Available through UK retailers by August 2026, the PIXL 5K sits alongside the existing 12ml PIXL 8000. The UK's Vaping Products Duty took effect on October 1 at £0.22 per millilitre, producing theoretical duty amounts of £1.32 and £2.64 for the two products' respective full refill sets.
product
Oct.10
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands has agreed to acquire 100% of Swedish modern oral nicotine company Yoik Group AB for an initial SEK515 million, equivalent to about US$53.9 million, plus a deferred payment linked to performance over the next two years. Yoik owns nicotine pouch brand Helwit, which held about 3.4% of Sweden’s modern oral nicotine market over the past 12 months. Imperial says the acquisition will more than double its existing share of the Swedish market. Helwit is also sold elsewhere in the Nordics, through European online channels and in selected UK retail outlets.
Sep.08
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia’s Department of Home Affairs has hired Deloitte to provide data analytics, business-process, communications and project-delivery support to the Office of the Illicit Tobacco and E-Cigarette Commissioner. The government says Deloitte personnel do not provide policy advice to the Commissioner or the Australian government, with policy development and decision-making remaining with public officials. The arrangement has nevertheless drawn scrutiny because Deloitte has previously provided professional services to several tobacco and vaping companies.
Sep.03